Supplementary Table 1. Summary of information available on Mycobacterium infections in wild meerkats in the Kalahari, South Africa.
TB prevalence TB prevalence TB prevalence TB prevalence TB prevalence TB prevalence TB prevalence TB prevalence TB prevalence
Reference Exposure Clinical TB signs Confirmed TB infection Mortality TB detection Sample size Data collection Comments
Alexander et al., 2002 100% 100% N = 1 100% Signs, PM, MC N = 20 1998/1999 Tracking TB spread through 1 group following immigration of positive individual
Drewe, Foote et al., 2009 n.r. 91.2% 91.2% 91.2% PM, MC N = 57 2005 - 2007 Detailed pathology of 52 individuals euthanized for TB (5 individuals as control)
Drewe, Dean et al., 2009 46.7%* n.r. 13.2% n.r. MC, IRT N = 240 2005 - 2007 Exposure determined by immune-reaction assay
Drewe 2010 n.r. n.r. 9% to 33% n.r. MC, IRT N = 110 2006/2007 TB transmission study, prevalence reported in 3 months periods
Drewe et al., 2011 30%* n.r. n.r. n.r. MC, IRT N = 134 2006/2007 Exposure determined by immune-reaction assay, longitudinal testing of 37 individuals
Clarke et al., 2016 n.r. n.r. 34.7% n.r. IRT N=108 2014/2015 TB detected by immune-reaction assay, 24.7% to 82.4% depending on estimated exposure risk
Patterson et al., 2017 n.r. 6% 6% 6% Signs N = 2388 2001 - 2015 TB defined as clinical signs followed by TB related euthanasia
Patterson et al., 2021 n.r. 17.5% 8.95% 11.1% PM, MC, IRT, PCR N = 268 2014 - 2016 TB detection assay validation
Patterson et al., 2022 n.r. n.r. n.r. 19% MC, IRT N = 135 2014 - 2016 Intervention study
Duncan et al., 2021 n.r. 63% (group level) n.r. 63% (group level) Signs N = 98 groups 1993 - 2019 TB effect on demography
Donadio et al., 2022
100%
56.1%
60.6%
27.3%
Signs, PCR
N = 66
1998 - 2018
TB detection assay validation; individuals selected for likely TB exposure and signs; TB infections: 53% signs + PCR, 7.6% PCR only
present study 71% 16.1% n.r. 11.6% Signs N = 3420 1993 - 2020 TB quantification
B) TB progression B) TB progression B) TB progression B) TB progression B) TB progression B) TB progression B) TB progression B) TB progression B) TB progression
Reference Exposure – infection Exposure - signs Infection - signs Signs - death TB detection Sample size Data collection Comment
Alexander et al., 2002 n.r. ~6 and 14 m n.r. n.r. Signs, PM, MC N = 20 1998/1999 See above
Drewe 2010 10m (1.5-25.3m) n.r. n.r. MC, IRT N = 110 2006/2007 See above
Drewe et al., 2011 12.6m n.r. n.r. 8.1m (infection to death) MC, IRT N = 134 (37 longitudinal testing) 2006/2007 See above
Patterson et al., 2017 n.r. n.r. n.r. < 6 months Signs, TB related euthanasia N = 2388 2001 - 2015 See above
Duncan et al., 2021 n.r. n.r. n.r. 10 months (group level) Signs N = 98 groups 1993 - 2019 See above
Donadio et al., 2022 14.0 ± 10.8m n.r. 11.5 ± 6.9m 5.3 ± 5.7m Signs, PCR N = 66 1998 - 2018 See above
Present study n.r. 17.1 ± 13.8m n.r. 6.6 ± 10.8m Signs N = 3420 1993 - 2020 See above
Abbreviations: PM: post mortem examination; signs: clinical signs of TB; MC: Mycobacterial cultures; IRT: Immune response tests; n.r.: not reported *Positive in immune reaction assays For all studies, durations reported in days were transformed into months to allow easier comparison between studies Abbreviations: PM: post mortem examination; signs: clinical signs of TB; MC: Mycobacterial cultures; IRT: Immune response tests; n.r.: not reported *Positive in immune reaction assays For all studies, durations reported in days were transformed into months to allow easier comparison between studies Abbreviations: PM: post mortem examination; signs: clinical signs of TB; MC: Mycobacterial cultures; IRT: Immune response tests; n.r.: not reported *Positive in immune reaction assays For all studies, durations reported in days were transformed into months to allow easier comparison between studies Abbreviations: PM: post mortem examination; signs: clinical signs of TB; MC: Mycobacterial cultures; IRT: Immune response tests; n.r.: not reported *Positive in immune reaction assays For all studies, durations reported in days were transformed into months to allow easier comparison between studies Abbreviations: PM: post mortem examination; signs: clinical signs of TB; MC: Mycobacterial cultures; IRT: Immune response tests; n.r.: not reported *Positive in immune reaction assays For all studies, durations reported in days were transformed into months to allow easier comparison between studies Abbreviations: PM: post mortem examination; signs: clinical signs of TB; MC: Mycobacterial cultures; IRT: Immune response tests; n.r.: not reported *Positive in immune reaction assays For all studies, durations reported in days were transformed into months to allow easier comparison between studies Abbreviations: PM: post mortem examination; signs: clinical signs of TB; MC: Mycobacterial cultures; IRT: Immune response tests; n.r.: not reported *Positive in immune reaction assays For all studies, durations reported in days were transformed into months to allow easier comparison between studies Abbreviations: PM: post mortem examination; signs: clinical signs of TB; MC: Mycobacterial cultures; IRT: Immune response tests; n.r.: not reported *Positive in immune reaction assays For all studies, durations reported in days were transformed into months to allow easier comparison between studies Abbreviations: PM: post mortem examination; signs: clinical signs of TB; MC: Mycobacterial cultures; IRT: Immune response tests; n.r.: not reported *Positive in immune reaction assays For all studies, durations reported in days were transformed into months to allow easier comparison between studies